Fideuram Intesa Sanpaolo Private Banking S.P.A. Makes New $5.26 Million Investment in Medline $MDLN

Fideuram Intesa Sanpaolo Private Banking S.P.A. purchased a new stake in shares of Medline (NASDAQ:MDLN) during the first quarter, Holdings Channel.com reports. The firm purchased 118,251 shares of the company’s stock, valued at approximately $5,262,000.

Other large investors have also recently made changes to their positions in the company. Carlyle Group Inc. purchased a new stake in shares of Medline in the 4th quarter valued at $9,042,728,000. H&F Corporate Investors X Ltd. purchased a new position in Medline in the 4th quarter worth $4,179,591,000. Vanguard Group Inc. purchased a new position in Medline in the 4th quarter worth $793,278,000. Morgan Stanley bought a new stake in Medline in the fourth quarter worth $636,807,000. Finally, Capital Research Global Investors bought a new stake in Medline in the fourth quarter worth $620,937,000.

Medline Price Performance

Shares of MDLN stock opened at $43.19 on Friday. The stock has a market capitalization of $56.74 billion and a price-to-earnings ratio of 134.97. The business has a fifty day simple moving average of $38.38. Medline has a 52 week low of $32.81 and a 52 week high of $50.88. The company has a debt-to-equity ratio of 0.65, a current ratio of 4.41 and a quick ratio of 2.51.

Medline (NASDAQ:MDLN) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.33 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.29 by $0.04. The company had revenue of $7.35 billion for the quarter. The company’s quarterly revenue was up 10.7% compared to the same quarter last year. Equities research analysts anticipate that Medline will post 1.49 earnings per share for the current year.

Insider Transactions at Medline

In other Medline news, insider Douglas P. Golwas sold 100,000 shares of Medline stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $36.77, for a total transaction of $3,677,000.00. Following the sale, the insider directly owned 23,899 shares of the company’s stock, valued at approximately $878,766.23. The trade was a 80.71% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Jessi L. Corcoran bought 5,000 shares of Medline stock in a transaction on Friday, June 5th. The shares were purchased at an average price of $34.15 per share, for a total transaction of $170,750.00. Following the acquisition, the insider directly owned 5,000 shares in the company, valued at approximately $170,750. This trade represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders own 0.81% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on MDLN. Robert W. Baird reduced their price objective on Medline from $57.00 to $45.00 and set an “outperform” rating on the stock in a research note on Wednesday, June 3rd. William Blair reissued an “outperform” rating on shares of Medline in a research note on Thursday, June 4th. BNP Paribas Exane dropped their target price on Medline from $49.00 to $40.00 and set a “neutral” rating for the company in a report on Thursday, May 14th. Barclays reduced their price target on Medline from $50.00 to $45.00 and set an “overweight” rating on the stock in a research report on Monday, June 1st. Finally, Sanford C. Bernstein decreased their price target on Medline from $56.00 to $54.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Medline presently has a consensus rating of “Moderate Buy” and an average target price of $50.54.

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.